ENLV Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

1.137

Open

1.120

VWAP

1.09

Vol

222.46K

Mkt Cap

265.87M

Low

1.060

Amount

242.29K

EV/EBITDA(TTM)

--

Total Shares

237.38M

EV

247.66M

EV/OCF(TTM)

--

P/S(TTM)

--

Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

Show More

Events Timeline

(ET)

2026-02-10

08:10:00

Enlivex Therapeutics RAIN Token Listed on Kraken

2026-01-26 (ET)

2026-01-26

08:10:00

Enlivex Therapeutics RAIN Token Listed on WhiteBIT

2026-01-07 (ET)

2026-01-07

08:31:00

Enlivex Therapeutics RAIN Token Listed on KuCoin

2025-12-23 (ET)

2025-12-23

16:40:00

Enlivex Therapeutics Files to Sell 212M Ordinary Shares

2025-11-26 (ET)

2025-11-26

08:09:05

Enlivex Therapeutics Completes $212 Million Private Placement

2025-11-24 (ET)

2025-11-24

07:58:20

Enlivex Therapeutics sets price for 212 million shares at $1.00 in private placement.

News

Benzinga

Enlivex Therapeutics' RAIN Token Listed on KuCoin, Expected to Enhance Liquidity

Globenewswire

2025-11-26Globenewswire

Enlivex Adopts First RAIN Prediction Market Token Strategy, Secures $212 Million Funding

TipRanks

2025-11-25TipRanks

Three Penny Stocks to Keep an Eye On as of November 25, 2025

Benzinga

2025-11-24Benzinga

Dow Rises by 300 Points; Waldencast Stock Takes a Dive

Newsfilter

2025-11-24Newsfilter

Enlivex Secures $212 Million PIPE and Appoints Former Italian PM Matteo Renzi to Board

Benzinga

2025-11-24Benzinga

D. Boral Capital Lowers Enlivex Therapeutics Rating to Hold

2 Analyst Rating

Wall Street analysts forecast ENLV stock price to rise

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

13.00

Averages

13.00

High

13.00

Current: 0.000

Low

13.00

Averages

13.00

High

13.00

D. Boral Capital

D. Boral Capital

Buy -> Hold

downgrade

AI Analysis

2025-11-24

Reason

D. Boral Capital

D. Boral Capital

Price Target

AI Analysis

2025-11-24

downgrade

Buy -> Hold

Reason

D. Boral Capital downgraded Enlivex Therapeutics to Hold from Buy with no price target after the company announced a $212M private placement for 212M shares priced at $1.00 to initiate a digital asset treasury strategy centered on the accumulation of RAIN tokens designed for on-chain predictive markets, options trading, and transparent data aggregation. The firm, which notes its valuation models had been based on the value of the therapeutic, says those are "less relevant now" and it needs some time to understand how to value the company following the shift.

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$13

2025-04-21

Reason

D. Boral Capital

Jason Kolbert

Price Target

$13

2025-04-21

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Enlivex Ltd (ENLV.O) is -1.45, compared to its 5-year average forward P/E of -3.51. For a more detailed relative valuation and DCF analysis to assess Enlivex Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-3.51

Current PE

-1.45

Overvalued PE

-1.02

Undervalued PE

-5.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

best penny stocks to buy short term

Intellectia · 30 candidates

Market Cap: <= 1000.00MRegion: USPrice: $0.50 - $5.00List Exchange: XNYS, XNAS, XASEWeek Price Change Pct: $5.00 - $50.00One Week Rise Prob: >= 60Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

NIU Technologies

265.08M

Greenland Technologies Holding Corp

18.96M

AMC Entertainment Holdings Inc

759.16M

Enlivex Therapeutics Ltd

275.36M

Estrella Immunopharma Inc

60.95M

Protalix Biotherapeutics Inc

232.42M

stocks between $1.00 and $1.10

Intellectia · 54 candidates

Price: $1.00 - $1.10

Ticker

Name

Market Cap$

Adagio Medical Holdings Inc

22.87M

Heidmar Maritime Holdings Corp

61.90M

CCSC Technology International Holdings Ltd

4.15M

Auddia Inc

3.35M

Estrella Immunopharma Inc

42.45M

CytoMed Therapeutics Ltd

11.15M

Intellectia · 388 candidates

Price: <= $1.00

Ticker

Name

Market Cap$

Strive Inc

1.11B

Wheels Up Experience Inc

624.57M

Canaan Inc

498.64M

Datavault AI Inc

433.82M

Beyond Meat Inc

424.50M

agilon health inc

395.14M

stocks under $1 likely to be bullish today

Intellectia · 11 candidates

Price: <= $1.00Relative Vol: >= 1Week Price Change Pct: >= $0.00Option Sentiments: Bullish

Ticker

Name

Market Cap$

TRX Gold Corp

271.29M

BRC Inc

247.13M

Enlivex Therapeutics Ltd

232.87M

Ring Energy Inc

203.08M

PLAYSTUDIOS Inc

79.38M

NeuroOne Medical Technologies Corp

45.64M

thereapidics stocks under 1.00

Intellectia · 388 candidates

Price: <= $1.00

Ticker

Name

Market Cap$

Strive Inc

1.11B

Wheels Up Experience Inc

624.57M

Canaan Inc

498.64M

Datavault AI Inc

433.82M

Beyond Meat Inc

424.50M

agilon health inc

395.14M

Whales Holding ENLV

Trading Trends

People Also Watch

Frequently Asked Questions

What is Enlivex Ltd (ENLV) stock price today?

The current price of ENLV is 1.07 USD — it has decreased -4.46

What is Enlivex Ltd (ENLV)'s business?

Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

What is the price predicton of ENLV Stock?

Wall Street analysts forecast ENLV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENLV is13.00 USD with a low forecast of 13.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Enlivex Ltd (ENLV)'s revenue for the last quarter?

Enlivex Ltd revenue for the last quarter amounts to 0.00 USD, decreased

What is Enlivex Ltd (ENLV)'s earnings per share (EPS) for the last quarter?

Enlivex Ltd. EPS for the last quarter amounts to -0.09 USD, decreased -25.00

How many employees does Enlivex Ltd (ENLV). have?

Enlivex Ltd (ENLV) has 36 emplpoyees as of March 12 2026.

What is Enlivex Ltd (ENLV) market cap?

Today ENLV has the market capitalization of 265.87M USD.